Progress of research on PD-1/PD-L1 in leukemia
Leukemia cells prevent immune system from clearing tumor cells by inducing the immunosuppression of the bone marrow (BM) microenvironment. In recent years, further understanding of the BM microenvironment and immune landscape of leukemia has resulted in the introduction of several immunotherapies, i...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1265299/full |
| _version_ | 1827805961836822528 |
|---|---|
| author | Huizhen Cao Tianyu Wu Xue Zhou Shuyang Xie Hongfang Sun Yunxiao Sun Youjie Li |
| author_facet | Huizhen Cao Tianyu Wu Xue Zhou Shuyang Xie Hongfang Sun Yunxiao Sun Youjie Li |
| author_sort | Huizhen Cao |
| collection | DOAJ |
| description | Leukemia cells prevent immune system from clearing tumor cells by inducing the immunosuppression of the bone marrow (BM) microenvironment. In recent years, further understanding of the BM microenvironment and immune landscape of leukemia has resulted in the introduction of several immunotherapies, including checkpoint inhibitors, T-cell engager, antibody drug conjugates, and cellular therapies in clinical trials. Among them, the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis is a significant checkpoint for controlling immune responses, the PD-1 receptor on tumor-infiltrating T cells is bound by PD-L1 on leukemia cells. Consequently, the activation of tumor reactive T cells is inhibited and their apoptosis is promoted, preventing the rejection of the tumor by immune system and thus resulting in the occurrence of immune tolerance. The PD-1/PD-L1 axis serves as a significant mechanism by which tumor cells evade immune surveillance, and PD-1/PD-L1 checkpoint inhibitors have been approved for the treatment of lymphomas and varieties of solid tumors. However, the development of drugs targeting PD-1/PD-L1 in leukemia remains in the clinical-trial stage. In this review, we tally up the basic research and clinical trials on PD-1/PD-L1 inhibitors in leukemia, as well as discuss the relevant toxicity and impacts of PD-1/PD-L1 on other immunotherapies such as hematopoietic stem cell transplantation, bi-specific T-cell engager, chimeric antigen receptor T-cell immunotherapy. |
| first_indexed | 2024-03-11T21:33:40Z |
| format | Article |
| id | doaj.art-3884756688fe4b989ed7493b3cb715f2 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-11T21:33:40Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-3884756688fe4b989ed7493b3cb715f22023-09-27T04:53:46ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-09-011410.3389/fimmu.2023.12652991265299Progress of research on PD-1/PD-L1 in leukemiaHuizhen Cao0Tianyu Wu1Xue Zhou2Shuyang Xie3Hongfang Sun4Yunxiao Sun5Youjie Li6Department of Pediatrics, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, ChinaDepartment of Gastrointestinal Surgery, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, ChinaDepartment of Pediatrics, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, ChinaDepartment of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, ChinaDepartment of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, ChinaDepartment of Pediatrics, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, ChinaDepartment of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, ChinaLeukemia cells prevent immune system from clearing tumor cells by inducing the immunosuppression of the bone marrow (BM) microenvironment. In recent years, further understanding of the BM microenvironment and immune landscape of leukemia has resulted in the introduction of several immunotherapies, including checkpoint inhibitors, T-cell engager, antibody drug conjugates, and cellular therapies in clinical trials. Among them, the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis is a significant checkpoint for controlling immune responses, the PD-1 receptor on tumor-infiltrating T cells is bound by PD-L1 on leukemia cells. Consequently, the activation of tumor reactive T cells is inhibited and their apoptosis is promoted, preventing the rejection of the tumor by immune system and thus resulting in the occurrence of immune tolerance. The PD-1/PD-L1 axis serves as a significant mechanism by which tumor cells evade immune surveillance, and PD-1/PD-L1 checkpoint inhibitors have been approved for the treatment of lymphomas and varieties of solid tumors. However, the development of drugs targeting PD-1/PD-L1 in leukemia remains in the clinical-trial stage. In this review, we tally up the basic research and clinical trials on PD-1/PD-L1 inhibitors in leukemia, as well as discuss the relevant toxicity and impacts of PD-1/PD-L1 on other immunotherapies such as hematopoietic stem cell transplantation, bi-specific T-cell engager, chimeric antigen receptor T-cell immunotherapy.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1265299/fullleukemiaprogrammed cell death protein 1programmed death-ligand 1immunotherapyPD-1/PD-L1 mAbs |
| spellingShingle | Huizhen Cao Tianyu Wu Xue Zhou Shuyang Xie Hongfang Sun Yunxiao Sun Youjie Li Progress of research on PD-1/PD-L1 in leukemia Frontiers in Immunology leukemia programmed cell death protein 1 programmed death-ligand 1 immunotherapy PD-1/PD-L1 mAbs |
| title | Progress of research on PD-1/PD-L1 in leukemia |
| title_full | Progress of research on PD-1/PD-L1 in leukemia |
| title_fullStr | Progress of research on PD-1/PD-L1 in leukemia |
| title_full_unstemmed | Progress of research on PD-1/PD-L1 in leukemia |
| title_short | Progress of research on PD-1/PD-L1 in leukemia |
| title_sort | progress of research on pd 1 pd l1 in leukemia |
| topic | leukemia programmed cell death protein 1 programmed death-ligand 1 immunotherapy PD-1/PD-L1 mAbs |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1265299/full |
| work_keys_str_mv | AT huizhencao progressofresearchonpd1pdl1inleukemia AT tianyuwu progressofresearchonpd1pdl1inleukemia AT xuezhou progressofresearchonpd1pdl1inleukemia AT shuyangxie progressofresearchonpd1pdl1inleukemia AT hongfangsun progressofresearchonpd1pdl1inleukemia AT yunxiaosun progressofresearchonpd1pdl1inleukemia AT youjieli progressofresearchonpd1pdl1inleukemia |